Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bayesian Meta Analysis of Ivermectin Effectiveness in Treating Covid-19 Disease

Neil et al., ResearchGate, doi:10.13140/RG.2.2.31800.88323
Jul 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Bayesian analysis of a subset of ivermectin trial data concluding that there is overwhelming evidence to support a causal link between ivermectin, COVID-19 severity, and mortality.
7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.
Currently there are 104 ivermectin for COVID-19 studies, showing 48% lower mortality [35‑59%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].
Neil et al., 12 Jul 2021, preprint, 2 authors.
This PaperIvermectinAll
Bayesian Meta Analysis of Ivermectin Effectiveness in Treating Covid-19 Disease
Martin Neil, Norman Fenton
A recent peer reviewed meta-analysis evaluating ivermectin (Bryant et al, 2021) concluded that this antiparasitic drug is a cheap and effective treatment for reducing Covid-19 deaths. These conclusions were in stark contrast to those of a later study (Roman et al, 2021) . Although (Roman et al, 2021) applied the same classical statistical approach to meta-analysis, and produced similar results based on a subset of the same trials data used by (Bryant et al), they claimed there was insufficient quality of evidence to support the conclusion Ivermectin was effective. This paper applies a Bayesian approach, to a subset of the same trial data, to test several causal hypotheses linking Covid-19 severity and ivermectin to mortality and produce an alternative analysis to the classical approach. Applying diverse alternative analysis methods which reach the same conclusions should increase overall confidence in the result. We show that there is overwhelming evidence to support a causal link between ivermectin, Covid-19 severity and mortality, and: i) for severe Covid-19 there is a 90.7% probability the risk ratio favours ivermectin; ii) for mild/moderate Covid-19 there is an 84.1% probability the risk ratio favours ivermectin. Also, from the Bayesian meta-analysis for patients with severe Covid-19, the mean probability of death without ivermectin treatment is 22.9%, whilst with the application of ivermectin treatment it is 11.7%. The paper also highlights advantages of using Bayesian methods over classical statistical methods for meta-analysis.
Appendix The stages in the analysis are organised as follows: A. Learn the mortality probability distribution from relevant trials for each hypothesis of concern using a Beta-Binomial hierarchical model. B. For each causal hypothesis use the model in stage A to learn the mortality probability distributions relevant to that causal hypothesis. C. For each causal hypothesis use the learnt probability distributions from stage B to predict the observed data and calculate the likelihood of observing that data. D. all causal hypotheses compute the posterior probability of each hypothesis given the likelihood of observing the data under hypothesis and select the most likely causal hypothesis that explains the data. E. Estimate the magnitude of impact of the relevant variables, under that hypothesis, on mortality. For each hypothesis and combination of Covid-19 severity and treatment variable state we learn the corresponding mortality probability distribution using a hierarchical Beta-Binomial model (where 𝑚 is the number of studies, 𝑛 𝑖 is the number of patients and 𝑥 𝑖 is the number of deaths in study 𝑖): 𝛼, 𝛽 ~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,100) where the mortality probability, 𝑝, is determined by two parameters, 𝛼 and 𝛽 that model the global distribution of 𝑝 𝑖 variables across the studies, where each 𝑝 𝑖 is determined by its local data (𝑛 𝑖 , 𝑥 𝑖 ). An example of the structure of the Bayesian model used in steps A to C is shown in Figure 4 , as a Bayesian Network, where we learn the probability..
Crawford, Fenton, The Meta-Analytical Fixers: An Ivermectin Tale
Fordham, Lawrie, Attempt to discredit landmark British ivermectin study
Ltd, Bryant, Lawrie, Dowswell, Fordham et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402
Roman, Burela, Pasupuleti, Piscoya, Vidal et al., Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials, MedRxiv, doi:10.1101/2021.05.21.21257595
{ 'type': 'article-journal', 'id': '', 'language': 'en', 'author': [{'family': 'Neil', 'given': 'Martin'}, {'family': 'Fenton', 'given': 'Norman'}], 'issued': {'date-parts': [[2021]]}, 'container-title': 'Unpublished', 'DOI': '10.13140/RG.2.2.31800.88323', 'publisher': 'Unpublished', 'title': 'Bayesian Meta Analysis of Ivermectin Effectiveness in Treating Covid-19 Disease', 'URL': ''}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop